Navigation Links
International Trachoma Initiative and the Task Force for Child Survival and Development Announce New Merger to Eliminate Blinding Trachoma and Fight Against Other Neglected Tropical Diseases
Date:3/18/2009

NEW YORK, March 18 /PRNewswire-USNewswire/ -- The International Trachoma Initiative (ITI) and the Task Force for Child Survival and Development announced today that they will join forces to leverage resources and scale up efforts to eliminate blinding trachoma. Trachoma, a Neglected Tropical Disease (NTD) that is the world's leading cause of preventable blindness, affects 41 million people in 56 countries. While trachoma can be prevented and cured, an estimated 6.8 million people have already lost some or all of their sight to trachoma, and an additional 8.2 million people are at risk of irreversible blindness.

"ITI is excited by the enormous potential that this merger brings to eliminating blinding trachoma," said Ibrahim Jabr, ITI President. "We realized in 2006 that to increase the impact of global trachoma control efforts, ITI would need a complementary partner to help us meet the WHO goal of elimination by 2020. We are confident that the Task Force is that partner."

ITI was created in 1998 through a public-private partnership of the Edna McConnell Clark Foundation and Pfizer, and since then, has been the only global organization dedicated exclusively to the elimination of blinding trachoma.

"Pfizer is confident that the merger between ITI and the Task Force is a positive step forward in ridding the world of blinding trachoma. Pfizer is pleased with the progress we have made with our partners over the last ten years -- providing over a billion dollars of pharmaceutical and financial donations -- that has helped break the cycle of poverty trachoma imposes on millions of families and communities world-wide. We look forward to continuing our support and working through ITI and its Trachoma Expert Committee to provide the Zithromax that will be needed to eliminate blinding trachoma by 2020 and restore the health and well-being of families now and generations to come," said Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer Inc.

"The mission and goals of ITI are a strong complement to the Task Force mission," stated Mark Rosenberg, M.D., Executive Director of the Task Force. "We are at an important juncture for trachoma control efforts and this commitment from Pfizer to supply Zithromax will help mobilize the partners essential to the success of this mission."

ITI is a major proponent and facilitator of the SAFE strategy to prevent, treat and ultimately eliminate blinding trachoma through Surgery, Antibiotics, Facial cleanliness, and Environmental improvements. The Atlanta-based Task Force, working with CARE USA, provides a forum for sharing knowledge and expertise in these four program areas, especially in the area of integration of mass drug administration, sanitation and safe water, and houses programs that address onchocerciasis (river blindness), lymphatic filariasis (elephantiasis), and intestinal worms -- three NTDs whose prevention and treatment could be linked to trachoma control.


'/>"/>
SOURCE The International Trachoma Initiative (ITI)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
3. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
4. LCA Hails International Investigators Studying Lung Cancer
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. Medical Services International Maintains Pace in Second Quarter
8. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
9. International Gateway Insurance Brokers Partners With MEDILINQ
10. Tulane University to receive $14M for international HIV/AIDS program
11. International Database Seeks to Boost Treatment of Altitude Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... ... , ... International Protein, a company based out of Australia that focuses on ... ECRM trade show in Hilton Head, SC. , International Protein was founded by ... line of products that would elevate her fitness regime. At this ECRM trade show, ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Mary Magdalene: Grace ... mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is ... who spent her career as an educator interacting with countless women who had little ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study ... Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Land ... brings attention to the issue of world hunger, and shares the simple and achievable ... Brubaker, devoted husband and member of the Fairview Missionary Church in Angola, Indiana where ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food and ... Chronic Idiopathic Constipation (CIC) in adult patients. ... gastrointestinal disorders," said Julie Beitz , M.D., director of ... for Drug Evaluation and Research. "With the availability of new ... treatment for their condition." ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
Breaking Medicine Technology: